Goldman Sachs Group Inc 4 D Molecular Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,274,973 shares of FDMT stock, worth $19.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,274,973
Previous 3,591,030
19.05%
Holding current value
$19.3 Million
Previous $38.8 Million
38.66%
% of portfolio
0.0%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding FDMT
# of Institutions
147Shares Held
46.7MCall Options Held
121KPut Options Held
33.2K-
Black Rock Inc. New York, NY4.9MShares$22.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$20.6 Million0.41% of portfolio
-
Vr Adviser, LLC New York, NY2.95MShares$13.3 Million2.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$12.9 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.67MShares$12.1 Million0.56% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $146M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...